|
|
|
Development of a therapeutic vaccine against prostate cancer |
Therapeutic area |
Cancer |
Goal |
The development of a vaccine formulation to generate a therapeutic immune response against the autologus GnRH, produce testosterone ablation and prostate atrophy. |
Description |
Prostate cancer is the second most common type of cancer in men. Worldwide more than 650 000 cases are diagnosis every year. It is estimated that 1 in 6 men in any moment of his life suffer from this disease. Around 30% of the diagnosed men die as consequence of their progression.
This project is carry out as part of the research developed in the CIGB, in Havana, Cuba, based on the generation of a completely synthetic GnRH peptide modified at position 6 and attached to the 830-844 tetanic toxoid (TT) helper T-cell sequence, which was specially adjuvated. The main results obtained so far are:
1-In animal models, important preclinical evidences were obtained in pigs, dogs, rats and in non-human primates, where a significant decrease in the size of testes (p<0.001), prostate (p<0.01), and consequently testosterone fall until castration was observed. In a murine model the immunization with this vaccine candidate produced a significant tumor growth inhibition of Dunning R3327-H androgen responsive prostate tumor and significant survival of immunized animals.
2-In the clinical trial Phase I an important milestone was to demonstrate the safety of this candidate. No important adverse effects were detected. The good immunogenicity of the vaccine candidate tested was in relation to the decrease of testosterone concentration, PSA normalization and prostate tumor reduction.
|
Patent Status |
1-Combination of growth-and hormone-regulating factors for the treatment of neoplasia. Eddy Bover Fuentes, Roberto Basulto Baker, Eulogio Pimentel Jesús A. Junco Barranco et al. PCT WO 2004/058297 A1. Filed in PCT, Cuba, South-Korea, India, and Russia.
2- A second patent has been applied for our vaccine candidate at the Cuban office of Industrial property. |
Project Status |
Phase I clinical trial finished.
|
Type of collaboration requested |
Corporate partnership for carrying out clinical trials.
|
Competitives advantages Milestones |
Experience in genetic engineering and experimental oncology, highly skilled staff, versatility of the technology (either peptide- or protein-based). Milestones to be developed jointly with the partner.
After the phase I clinical trial in the evaluation of safety, immunogenicity and preliminary therapeutic efficacy of the vaccine candidate, a therapeutic clinical trials Phase II in patients should be conducted.
|
Host Insitutions |
Center for Genetic Engineering and Biotechnology (CIGB). Ave 31, e/158 y 190 Cubanacán, Playa. Apdo. 6996, La Habana, 10600, Cuba . Tel. (53-7) 2712397; 2716022. Fax. (53-7) 2736008; 2718070. email: ernesto.lopez@cigb.edu.cu .
Web site: http://gndp.cigb.edu.cu |
Project code:
|
BIO/CIGB/2008-07
|
|
|
